
Sign up to save your podcasts
Or


A secondary analysis of a multicenter randomized trial suggests that the R-ACVBP regimen may improve outcomes in younger patients with the non-germinal center B-cell subtype of diffuse large B-cell lymphoma.
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
A secondary analysis of a multicenter randomized trial suggests that the R-ACVBP regimen may improve outcomes in younger patients with the non-germinal center B-cell subtype of diffuse large B-cell lymphoma.

14,359 Listeners

139 Listeners

319 Listeners

498 Listeners

58 Listeners

112,751 Listeners

44 Listeners

32 Listeners

195 Listeners

91 Listeners

363 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners